Article
A Fifteen-Gene Classifier to Predict Neoadjuvant Chemotherapy Responses in Patients with Stage IB to IIB Squamous Cervical Cancer.
Advanced science (Weinheim, Baden-Wurttemberg, Germany) - 1 May 2021
Tian Xun, Wang Xin, Cui Zifeng, Liu Jia, Huang Xiaoyuan, Shi Caixia, Zhang Min, Liu Ting, Du Xiaofang, Li Rui, Huang Lei, Gong Danni, Tian Rui, Cao Chen, Jin Ping, Zeng Zhen, Pan Guangxin, Xia Meng, Zhang Hongfeng, Luo Bo, Xie Yonghui, Li Xiaoming, Li Tianye, Wu Jun, Zhang Qinghua, Chen Gang, Hu Zheng
Abstract excerpt
Neoadjuvant chemotherapy (NACT) remains an attractive alternative for controlling locally advanced cervical cancer. However, approximately 15-34% of women do not respond to induction therapy. To develop a risk stratification tool, 56 patients with stage IB-IIB cervical cancer are included in 2 research centers from the discovery cohort. Patient-specific somatic mutations led to NACT non-responsiveness are...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.